Tekmira Pharmaceuticals has announced a merger with the US firm OnCore Biopharma. The merger would combine work on treatment, and a cure, for Hepatitis B which affects as many as 350 million people worldwide. Vancouver’s Tekmira has also recently supplied an experimental treatment for Ebola. Its stock surged 40 per cent on news of the merger.
More market talk: